<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00718536</url>
  </required_header>
  <id_info>
    <org_study_id>RALqd-ATV</org_study_id>
    <nct_id>NCT00718536</nct_id>
  </id_info>
  <brief_title>Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy</brief_title>
  <official_title>Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Germans Trias i Pujol Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The co-administration of raltegravir with medicinal products that are knouwn to be potent&#xD;
      UGT1A1 inhibitors, such as atazanavir, may increase plasma levels of raltegravir. So once&#xD;
      daily raltegravir (800 mg QD), instead of twice a day (400 mg BID), could be an appropriate&#xD;
      therapeutic option in HIV-infected patients also receiving atazanavir-containing&#xD;
      antiretroviral regimens. In this study, pharmacokinetic data supporting this hypothesis are&#xD;
      recovered.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment adherence is crucial for the effectiveness of antiretroviral therapy, and, in an&#xD;
      attempt to promote treatment adherence by the patients, once daily (QD) regimens are&#xD;
      preferred rather than twice daily (BID) regimens.&#xD;
&#xD;
      The dose of 400 mg BID of raltegravir has been recently licensed for the treatment of human&#xD;
      immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients.&#xD;
&#xD;
      Raltegravir is eliminated mainly by metabolism via uridine diphosphate glucuronyl transferase&#xD;
      (UGT1A1)-mediated glucuronidation pathway. Thus, co-administration of raltegravir with&#xD;
      medicinal products that are known to be potent UGT1A1 inhibitors, such as atazanavir, may&#xD;
      increase plasma levels of raltegravir.&#xD;
&#xD;
      Based on these data, it could be hypothesized that once daily raltegravir (800 mg QD) could&#xD;
      be an appropriate therapeutic option in HIV-infected patients also receiving&#xD;
      atazanavir-containing antiretroviral regimens. However, pharmacokinetic data supporting this&#xD;
      hypothesis are lacking.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Raltegravir area under the curve (AUC) 24 hours and Cmin</measure>
    <time_frame>Day 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Baseline (BL), Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>BL, Day 10</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Addition of raltegravir 800 mg QD to HAART</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Addition of raltegravir 800 mg QD to HAART</intervention_name>
    <description>Addition of raltegravir 800 mg QD to HAART</description>
    <arm_group_label>1</arm_group_label>
    <other_name>HAART+RAL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 18 to 65 years old with documented HIV-1 infection.&#xD;
&#xD;
          2. Patients on antiretroviral regimen that includes atazanavir 400mg QD for at least 4&#xD;
             weeks.&#xD;
&#xD;
          3. Complete virological suppression (&lt;50 copies/mL) for at least 12 months.&#xD;
&#xD;
          4. Voluntary written informed consent.&#xD;
&#xD;
          5. Ability of compliance with visit schedule.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. AIDS defining condition within 4 weeks prior to the initiation of the study.&#xD;
&#xD;
          2. Concomitant treatment with ritonavir as well as with inducers (NNRTI, rifampin,&#xD;
             carbamazepine, phenytoin, phenobarbital, valproic acid, etc) or inhibitors&#xD;
             (probenecid, etc) of the uridine diphosphate glucuronyl transferase within 2 weeks&#xD;
             before the screening visit.&#xD;
&#xD;
          3. Concomitant therapy with tenofovir.&#xD;
&#xD;
          4. History or suspected poor adherence to HAART.&#xD;
&#xD;
          5. History of drug allergy to raltegravir&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clotet Bonaventura, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lluita contra la Sida Foundation, HIV Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Germans Trias i Pujol Hospital</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 16, 2008</study_first_submitted>
  <study_first_submitted_qc>July 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2008</study_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atazanavir</keyword>
  <keyword>Raltegravir</keyword>
  <keyword>once-daily</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

